Research and Markets releases a new report: Competitor Analysis on Therapeutic Proteins

June 27, 2013 2:32 PM

Research and Markets has announced the addition of the “Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors” report to their offering.

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

– Erythropoietin (EPO) & Erythr
– G-CSF & GM-CSF
– Thrombopoietin & Thrombopoies
– Interferon
– Insulin
– Coagulation Factors
– Human Growth Hormone (hGH)
– FSH, hCG and LH: Therapeutic
– Thrombolytics & Fibrinolytics
– Enzyme Replacement Therapies

Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.

For more information visit http://www.researchandmarkets.com

 

Source: Research and Markets press release

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!